Oxytocin and Non-verbal Communication

July 25, 2017 updated by: Jean Liu, Yale-NUS College

Exploring the Effects of Oxytocin on Non-verbal Communication

In this protocol registration, the investigators plan a secondary data analysis of a dataset to explore the effects of intra-nasal oxytocin on the non-verbal expression of affiliation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Using Liu et al.'s (2012) dataset, the investigators seek to observe whether the administration of oxytocin modifies non-verbal communication with a stranger.

This dataset involves a conversation between two strangers that took place 45 minutes after drug administration. While Liu et al. coded the video for markers of interpersonal distance (physical distance, eye contact, conversational intimacy), the investigators seek to analyse oxytocin's effects on non-verbal communication of affiliative and sexual cues (e.g., smiles, lip puckers). Based on findings that oxytocin's effects depend on context, the investigators will explore these relationships as a function of the conversational context (where participants converse with each other using low-, medium-, and high-intimacy topics, or in an unstructured conversation).

Study Type

Interventional

Enrollment (Actual)

104

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • Sydney, New South Wales, Australia, 2052
        • University of New South Wales

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • healthy

Exclusion Criteria:

  • pregnant;
  • history of epilepsy, severe depression, severe anxiety, or psychosis;
  • smoking more than 15 cigarettes a day;
  • addicted to illegal substances.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Oxytocin
24IU Syntocinon, delivered in a single nose via a nasal spray
Drug: Oxytocin
Administration of the hormone oxytocin
Other Names:
  • Syntocinon
Placebo Comparator: Placebo
Matched nasal spray
Drug: Placebos

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Non-verbal communication
Time Frame: Measured in the interaction which commenced 45mins after drug administration
Based on coding the video-recorded interaction between two strangers, using a coding scheme by Gonzaga et al. (for affiliative and sexual cues)
Measured in the interaction which commenced 45mins after drug administration

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ratings of the person participants interacted with
Time Frame: Measured following the interaction (which commenced 45 mins after drug administration)
Positivity or sexual attraction towards the other participant in the conversation (as measured using visual analogue scales based on person perception studies)
Measured following the interaction (which commenced 45 mins after drug administration)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yale-NUS College

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2007

Primary Completion (Actual)

July 1, 2009

Study Completion (Actual)

July 1, 2009

Study Registration Dates

First Submitted

July 21, 2017

First Submitted That Met QC Criteria

July 21, 2017

First Posted (Actual)

July 25, 2017

Study Record Updates

Last Update Posted (Actual)

July 27, 2017

Last Update Submitted That Met QC Criteria

July 25, 2017

Last Verified

July 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IG15-B052

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Social Interaction

Clinical Trials on Placebos

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe